Patents Examined by Charanjit Aulakh
  • Organic electroluminescence device and organometallic compound for organic electroluminescence device
    Patent number: 11758805
    Abstract: An organic electroluminescence device of an embodiment includes a first electrode, a second electrode, and an emission layer between the first electrode and the second electrode, wherein the emission layer includes an organometallic compound represented by Formula 1, and the emission layer may show high emission efficiency properties.
    Type: Grant
    Filed: June 22, 2020
    Date of Patent: September 12, 2023
    Assignee: Samsung Display Co., Ltd.
    Inventors: Haejin Kim, Soo-Byung Ko, Sungbum Kim, Sujin Shin, Eunsoo Ahn, Eunyoung Lee, Jaesung Lee, Hyunjung Lee, Mina Jeon, Junghoon Han
  • Methods of using low dose naltrexone to treat chronic pain
    Patent number: 11752143
    Abstract: Methods of using low dose naltrexone to treat chronic pain in a patient. The methods of using low dose naltrexone to treat chronic pain generally includes administering to the patient a first amount of naltrexone in an immediate-release agent and a second amount of naltrexone in a modified-release agent.
    Type: Grant
    Filed: November 16, 2021
    Date of Patent: September 12, 2023
    Assignee: Soin Therapeutics LLC
    Inventor: Amol N. Soin
  • Pharmaceutical compositions of a selective c-kit kinase inhibitor and methods for making and using same
    Patent number: 11744823
    Abstract: The present disclosure relates generally to pharmaceutical compositions of N-(5-(5-((1R,2S)-2-fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-2-methylphenyl)imidazo[1,2-a]pyridine-3-carboxamide useful as a selective inhibitor of c-kit kinase and uses of the same in the treatment of c-kit kinase associated diseases.
    Type: Grant
    Filed: November 19, 2021
    Date of Patent: September 5, 2023
    Assignee: Third Harmonic Bio, Inc.
    Inventors: Gregg F. Keaney, Elizabeth Kwong
  • Process for extracting and purifying Rauwolscine from plant
    Patent number: 11739091
    Abstract: The present invention relates to a process for extracting an alkaloid. Particularly, the present invention relates to a process for extracting Rauwolscine from plant parts of Rauwolfia genus. Specifically, the present invention relates to a process for extracting Rauwolscine with an enhanced purity i.e. >95%.
    Type: Grant
    Filed: October 17, 2020
    Date of Patent: August 29, 2023
    Inventors: Ashok Sharma, Rakesh Nag
  • Inhibiting (?-v)(?-6) integrin
    Patent number: 11739087
    Abstract: Disclosed are small molecule inhibitors of ?v?6 integrin, and methods of using them to treat a number of diseases and conditions.
    Type: Grant
    Filed: April 23, 2021
    Date of Patent: August 29, 2023
    Assignee: Morphic Therapeutic, Inc.
    Inventors: Bryce A. Harrison, James E. Dowling, Matthew G. Bursavich, Dawn M. Troast, Blaise S. Lippa, Bruce N. Rogers, Kristopher N. Hahn, Cheng Zhong, Qi Qiao, Fu-Yang Lin, Brian Sosa, Aleksey I. Gerasyuto, Andrea Bortolato, Mats A. Svensson, Eugene Hickey, Kyle D. Konze, Tyler Day, Byungchan Kim
  • BODIPY-based rhombic metal ring, preparation method thereof, and application in near-infrared region imaging
    Patent number: 11738083
    Abstract: The present disclosure proposes a BODIPY-based rhombic metal ring, its preparation method, and application in near-infrared region imaging, specifically a BODIPY-based rhombic metal ring M absorbed in the near-infrared first region formed based on a BODIPY-based 120° bipyridyl BODIPY ligand molecule 1 and a 60° methoxy platinum acceptor molecule 2, self-assembled by Pt—N metal coordination bonds. The BODIPY-based rhombic supramolecular metal ring has good solubility and near-infrared fluorescence emission, and it is wrapped by commercial amphiphilic polymer F127 carrier to form F127/M nanoparticles, which successfully have excellent photodynamic and photothermal therapeutic effects in vitro.
    Type: Grant
    Filed: March 10, 2023
    Date of Patent: August 29, 2023
    Assignee: Hangzhou Normal University
    Inventors: Shouchun Yin, Yang Li, Huayu Qiu
  • Spiro compounds as glycosidase inhibitors
    Patent number: 11731972
    Abstract: Compounds of formula (I), wherein A, R, L, Z, Q1, Q2 and n have the meaning according to the claims, can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.
    Type: Grant
    Filed: August 22, 2019
    Date of Patent: August 22, 2023
    Assignee: Asceneuron SA
    Inventors: Anna Quattropani, Santosh S. Kulkarni, Paul Rakesh, Awadut Gajendra Giri
  • Organometallic compound, organic light-emitting device including the organometallic compound, and diagnostic composition including the organometallic compound
    Patent number: 11731994
    Abstract: An organometallic compound represented by Formula 1: M(L1)n1(L2)n2??Formula 1 wherein, in Formula 1, M is a transition metal, L1 is a ligand represented by Formula 2A, L2 is a ligand represented by Formula 2B, n1 is 1 or 2, wherein, when n1 is 2, two groups L1 are identical to or different from each other, n2 is 1 or 2, wherein, when n2 is 2, two group L2 are identical to or different from each other, the sum of n1 and n2 is 2 or 3, and L1 and L2 are different from each other wherein X1, ring CY1, ring CY2, ring CY14, R1 to R3, R11 to R14, Z1 to Z3, a1, a2, a3, b1, and c1 are the same as described in the description, and * and *? in Formulae 2A and 2B each indicate a binding site to M in Formula 1.
    Type: Grant
    Filed: November 26, 2019
    Date of Patent: August 22, 2023
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Kyuyoung Hwang, Seungyeon Kwak, Yoonhyun Kwak, Kum Hee Lee, Sunghun Lee, Whail Choi, Aram Jeon, Byoungki Choi, Hyeonho Choi
  • Compositions and methods for modulating the endothelial barrier
    Patent number: 11723910
    Abstract: Disclosed are compositions and methods for modulating endothelial barrier function.
    Type: Grant
    Filed: August 5, 2020
    Date of Patent: August 15, 2023
    Assignee: University of South Florida
    Inventors: Jerome William Breslin, Zeinab Yehia Khalil Motawe
  • EGFR inhibitors
    Patent number: 11718602
    Abstract: The present disclosure provides a compound represented by structural formula (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.
    Type: Grant
    Filed: August 8, 2022
    Date of Patent: August 8, 2023
    Assignee: Blueprint Medicines Corporation
    Inventors: Natasja Brooijmans, Jason D. Brubaker, John Emmerson Campbell, Christopher De Savi, Thomas A. Dineen, Meredith Suzanne Eno, Joseph L. Kim, Aysegul Ozen, Emanuele Perola, Brett D. Williams, Douglas Wilson, Kevin J. Wilson
  • Organometallic compound, organic light-emitting device including the same, and diagnostic composition including the organometallic compound
    Patent number: 11713333
    Abstract: Provided are an organometallic compound, an organic light-emitting device including the organometallic compound, and a diagnostic composition including the organometallic compound.
    Type: Grant
    Filed: June 4, 2020
    Date of Patent: August 1, 2023
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Aram Jeon, Seungyeon Kwak, Kum Hee Lee, Jun Chwae, Whail Choi, Kyuyoung Hwang, Yoonhyun Kwak, Byoungki Choi
  • Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof
    Patent number: 11708366
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; wherein R1 R2, R4 and X1 are defined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: August 12, 2021
    Date of Patent: July 25, 2023
    Assignee: Novartis AG
    Inventors: Mallesh Bushaboina, Xin Chen, Atwood Kim Cheung, Andrew James Culshaw, Timothy Brian Hurley, Nancy Labbe-Giguere, Wolfgang Miltz, David Orain, Tajesh Patel, Srinivasan Rajagopalan, Till Roehn, David Andrew Sandham, Gebhard Thoma, Ritesh Bhanudasji Tichkule, Rudolf Wälchli
  • Salt types, crystal forms, and preparation methods for benzopyrazole compounds as RHO kinase inhibitors
    Patent number: 11702400
    Abstract: Salt types, crystal forms, and preparation methods for benzopyrazole compounds as RHO kinase inhibitors. Specifically, disclosed are hydrochloride and acetate of compounds of formula (I) and crystal forms thereof, as well as application of the salt types and the crystal forms in preparation of RHO inhibitor drugs.
    Type: Grant
    Filed: October 16, 2020
    Date of Patent: July 18, 2023
    Assignee: MEDSHINE DISCOVERY INC.
    Inventors: Lingyun Wu, Zheming Xiao, Chunyan Jiang, Jian Li, Shuhui Chen
  • Antiviral compounds and method for treating RNA viral infection, particularly COVID-19
    Patent number: 11696911
    Abstract: The present invention provides a compound or a method for treating an RNA viral infection in a human, particularly COVID-19. The compound is a certain tricyclic compound.
    Type: Grant
    Filed: March 18, 2021
    Date of Patent: July 11, 2023
    Assignee: SENHWA BIOSCIENCES, INC.
    Inventor: Tai-Sen Soong
  • 3,9-diazaspiro[5,5]undecane compound as FLT3 and AXL inhibitors
    Patent number: 11691974
    Abstract: Disclosed in the present invention is a novel compound as FLT3 and AXL inhibitors. Specifically, disclosed are a compound represented by formula (I) and a pharmacologically acceptable salt thereof.
    Type: Grant
    Filed: September 27, 2019
    Date of Patent: July 4, 2023
    Assignee: MEDSHINE DISCOVERY INC.
    Inventors: Xiangyu Fu, Charles Z. Ding, Lihong Hu, Jianyu Lu, Wen Jiang, Jian Li, Shuhui Chen
  • Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
    Patent number: 11690836
    Abstract: Provided herein are solid forms comprising {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions comprising the solid forms, methods of making the solid forms and methods of their use for the treatment of various diseases and/or disorders.
    Type: Grant
    Filed: June 15, 2021
    Date of Patent: July 4, 2023
    Assignee: AKEBIA THERAPEUTICS, INC.
    Inventors: James Densmore Copp, Ann W. Newman, Anne Luong
  • MAGL inhibitors
    Patent number: 11691975
    Abstract: Provided herein are spirocyclic and fused bicyclic carbamates and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of MAGL. Furthermore, the subject compounds and compositions are useful for the treatment of pain.
    Type: Grant
    Filed: June 9, 2021
    Date of Patent: July 4, 2023
    Assignee: H. LUNDBECKA/S
    Inventors: Cheryl A. Grice, Daniel J. Buzard, Michael B. Shaghafi
  • Compounds for the treatment, alleviation or prevention of disorders associated with tau aggregates
    Patent number: 11684625
    Abstract: The present invention relates to novel compounds of formula (I) that can be employed in the treatment, alleviation or prevention of a group of disorders and abnormalities associated with Tau (Tubulin associated unit) protein aggregates including, but not limited to, Neurofibrillary Tangles (NFTs), such as Alzheimer's disease (AD).
    Type: Grant
    Filed: May 30, 2019
    Date of Patent: June 27, 2023
    Assignee: AC Immune SA
    Inventors: Sreenivasachary Nampally, Emanuele Gabellieri, Jerome Molette
  • Multivariate metal-organic frameworks for fine-tuning light emission
    Patent number: 11679372
    Abstract: Multivariate metal-organic framework compositions and methods of producing multivariate metal-organic frameworks. The metal-organic framework including at least one light-emitting linker in an amount sufficient for the composition to produce broadband emission spectra in high efficiencies.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: June 20, 2023
    Assignee: UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC.
    Inventors: Fernando J. Uribe-Romo, Jesus Cordova-Guerrero, Gavin S. Mohammad-Pour, Wesley Newsome
  • Capsid inhibitors for the treatment of HIV
    Patent number: 11680064
    Abstract: The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of a Retroviridae viral infection, including an infection caused by the HIV virus.
    Type: Grant
    Filed: June 24, 2021
    Date of Patent: June 20, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Chienhung Chou, Darryl Kato, Scott E. Lazerwith, John O. Link, Scott D. Schroeder, Winston C. Tse, Jennifer R. Zhang